Faron Pharmaceuticals Oy Holding(s) in Company (4177M)
July 28 2017 - 4:34AM
UK Regulatory
TIDMFARN TIDMAV.
RNS Number : 4177M
Faron Pharmaceuticals Oy
28 July 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Faron Pharmaceuticals Oy
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------------- --------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------------- -----------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
-------------------------------------------------------------------- -----------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
-------------------------------------------------------------------- -----------------------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------------- -----------------------------------
Other (please
specify):
----------------------------------------------------------- ------- -----------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- ------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
Chase (GA Group) Nominees Limited
1,151,067*
HSBC Global Custody Nominee
(UK) Limited 302,062*
State Street Nominees Limited
35,452*
* denotes direct interest
Chase (GA Group) Nominees Limited
57,059
Chase Nominees Limited 35,158
------------------------------------------------------------- ------------------------------------------
5. Date of the transaction 26 July 2017
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- ------------------------------------------
6. Date on which issuer 27 July 2017
notified:
------------------------------------------------------------- ------------------------------------------
7. Threshold(s) that is/are 6% to 5% Change at Combined
crossed or Interest Level. Figures are
reached: (vi, vii) provided in accordance with
provisions of your company
articles and not in fulfilment
of the requirements of the
Transparency Directive.
------------------------------------------------------------- ------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------------- ------------------------------ ---------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------------- ------------------ ---------- ------------ ---------------------- -------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------------- ------------------ ---------- ------------ ---------- ---------- ------- ----------
Ordinary
Shares
FI4000153309 1,910,798 1,910,798 1,580,798 1,488,581 92,217 5.33% 0.33%
------------------ ---------- ------------ ---------- ---------- ------- ----------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------- ------------------ ------------------------ ---------------------- -------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
-----------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------------- -------------------------------------
1,580,798 5.66%
-------------------------------------------------------- -------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
--------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
--------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
------------------------------------------------ ------------------
11. Number of voting rights proxy
holder will cease
to hold:
------------------------------------------------ ------------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------ ------------------
13. Additional information: Figures are based on a total
number of voting rights of
27,914,544 as per the company's
Announcement of 1 June 2017.
------------------------------- ---------------------------------
14. Contact name: Neil Whittaker, Aviva plc
------------------------------- ---------------------------------
15. Contact telephone number: 00 44 1603 684420
------------------------------- ---------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLFMGZNRRGGNZG
(END) Dow Jones Newswires
July 28, 2017 04:34 ET (08:34 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024